T-DM1 for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane

Squires H, Simpson E, Harvey R, Stevens J, Buckley Woods H, Stevenson M
Record ID 32014000166
English
Authors' objectives: To appraise the clinical and cost effectiveness of trastuzumab emtansine within its licensed indication for the treatment of unresectable locally advanced or metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane.
Details
Project Status: Completed
Year Published: 2014
Requestor: NIHR Health Technology Assessment programme
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England, United Kingdom
MeSH Terms
  • Trastuzumab
  • Breast Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
  • Antibodies, Monoclonal, Humanized
  • Maytansine
  • Ado-Trastuzumab Emtansine
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.